MX2023002422A - Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. - Google Patents
Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson.Info
- Publication number
- MX2023002422A MX2023002422A MX2023002422A MX2023002422A MX2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A MX 2023002422 A MX2023002422 A MX 2023002422A
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- disease
- therapeutic agent
- motor complications
- motor
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 206010030312 On and off phenomenon Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 abstract 2
- 229950000505 tandospirone Drugs 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020145967 | 2020-08-31 | ||
| PCT/JP2021/031722 WO2022045336A1 (ja) | 2020-08-31 | 2021-08-30 | パーキンソン病の運動合併症治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002422A true MX2023002422A (es) | 2023-03-22 |
Family
ID=80353469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002422A MX2023002422A (es) | 2020-08-31 | 2021-08-30 | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11628169B2 (https=) |
| EP (1) | EP4218764A4 (https=) |
| JP (1) | JPWO2022045336A1 (https=) |
| KR (1) | KR20230058615A (https=) |
| CN (1) | CN116113402A (https=) |
| AU (1) | AU2021332775A1 (https=) |
| CA (1) | CA3189670A1 (https=) |
| MX (1) | MX2023002422A (https=) |
| TW (1) | TW202227080A (https=) |
| WO (1) | WO2022045336A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116113402A (zh) * | 2020-08-31 | 2023-05-12 | 住友制药株式会社 | 帕金森病的运动并发症治疗药 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507303A (en) | 1981-12-22 | 1985-03-26 | Sumitomo Chemical Company, Limited | Succinimide derivatives, compositions and method of use |
| JPS58126865A (ja) | 1981-12-22 | 1983-07-28 | Sumitomo Chem Co Ltd | 環状イミド誘導体及びその酸付加塩 |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| JPH11228414A (ja) | 1998-02-06 | 1999-08-24 | Sumitomo Pharmaceut Co Ltd | タンドスピロン経皮剤 |
| JPH11228454A (ja) * | 1998-02-17 | 1999-08-24 | Sumitomo Chem Co Ltd | アルキニル置換アリールブロミド類の製造方法 |
| JP2002020291A (ja) | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | 認知機能障害の治療剤 |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| JPWO2005117886A1 (ja) | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
| ATE413166T1 (de) | 2004-11-22 | 2008-11-15 | Hisamitsu Pharmaceutical Co | Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff |
| JP4873871B2 (ja) | 2005-02-28 | 2012-02-08 | 久光製薬株式会社 | 粘着剤及び貼付剤 |
| JP5243254B2 (ja) | 2006-10-11 | 2013-07-24 | 久光製薬株式会社 | 結晶含有貼付剤 |
| CA2839350A1 (en) | 2011-07-05 | 2013-01-10 | Contera Pharma Aps | The use of serotonin receptor agonists for treatment of movement disorders |
| CN104411301B (zh) | 2012-04-18 | 2018-02-06 | 康特拉医药公司 | 适于改善运动障碍治疗的口服药物配方 |
| KR20210107729A (ko) * | 2018-12-20 | 2021-09-01 | 콘테라 파르마 에이/에스 | 운동 장애의 치료 |
| JP2020145967A (ja) | 2019-03-13 | 2020-09-17 | 日清食品ホールディングス株式会社 | プライマー及び特定昆虫の検出方法 |
| US10758535B1 (en) | 2019-04-26 | 2020-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Therapeutic drug for dyskinesia |
| WO2021166987A1 (ja) | 2020-02-19 | 2021-08-26 | 大日本住友製薬株式会社 | 経皮吸収製剤 |
| CN116113402A (zh) * | 2020-08-31 | 2023-05-12 | 住友制药株式会社 | 帕金森病的运动并发症治疗药 |
-
2021
- 2021-08-30 CN CN202180053119.3A patent/CN116113402A/zh active Pending
- 2021-08-30 US US17/461,024 patent/US11628169B2/en active Active
- 2021-08-30 MX MX2023002422A patent/MX2023002422A/es unknown
- 2021-08-30 WO PCT/JP2021/031722 patent/WO2022045336A1/ja not_active Ceased
- 2021-08-30 KR KR1020237005487A patent/KR20230058615A/ko not_active Withdrawn
- 2021-08-30 CA CA3189670A patent/CA3189670A1/en active Pending
- 2021-08-30 JP JP2022545758A patent/JPWO2022045336A1/ja active Pending
- 2021-08-30 AU AU2021332775A patent/AU2021332775A1/en not_active Abandoned
- 2021-08-30 TW TW110132143A patent/TW202227080A/zh unknown
- 2021-08-30 EP EP21861757.9A patent/EP4218764A4/en active Pending
-
2023
- 2023-02-24 US US18/113,887 patent/US20230241062A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116113402A (zh) | 2023-05-12 |
| WO2022045336A1 (ja) | 2022-03-03 |
| EP4218764A1 (en) | 2023-08-02 |
| US11628169B2 (en) | 2023-04-18 |
| KR20230058615A (ko) | 2023-05-03 |
| TW202227080A (zh) | 2022-07-16 |
| JPWO2022045336A1 (https=) | 2022-03-03 |
| CA3189670A1 (en) | 2022-03-03 |
| EP4218764A4 (en) | 2024-10-02 |
| US20220062282A1 (en) | 2022-03-03 |
| AU2021332775A9 (en) | 2024-09-26 |
| US20230241062A1 (en) | 2023-08-03 |
| AU2021332775A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| MX2022013647A (es) | Imidazopiridazinas como moduladores de il-17. | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| GEAP202416407A (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| PH12021553062A1 (en) | Pyrrolidine compounds | |
| MX2025005792A (es) | Combinaciones farmaceuticas y usos de las mismas | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| AU2017261286A1 (en) | Treatment of hair loss disorders with deuterated JAK inhibitors | |
| MX2024003770A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| NZ790364A (en) | Compounds and compositions for use in treating skin disorders | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| MX2024001840A (es) | Composiciones para usar en el tratamiento de neoplasias de celulas b. | |
| TW200639159A (en) | Treatment of pain | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| MX2024010615A (es) | Sales de un inhibidor de dihidroorotato deshidrogenasa (dhod) | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| MX2023009166A (es) | Derivados de quinoxalina y sus usos. | |
| MX2022012923A (es) | Inhibidores de trpc6 para tratar afecciones respiratorias. | |
| MX2022015146A (es) | Tratamiento de la artritis reumatoide. |